Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism

Prostate

Volumn 73, Issue 10, 2013, Pages 1028-1037

  Liu, Qiong ^a   Harvey, Chris T ^a   Geng, Hao ^a   Xue, Changhui ^a   Chen, Vivian ^a   Beer, Tomasz M ^a   Qian, David Z ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

chemotherapy response; docetaxel; JNK; MDH2; metabolism

Indexed keywords

CASPASE 3; CASPASE 7; COMPLEMENTARY DNA; DOCETAXEL; MALATE DEHYDROGENASE; MALATE DEHYDROGENASE 2; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL METABOLISM; CELL PROLIFERATION; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE; ENERGY METABOLISM; HUMANS; MALATE DEHYDROGENASE; MALE; MAP KINASE SIGNALING SYSTEM; OXYGEN CONSUMPTION; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; TAXOIDS;

EID: 84878436045     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22650     Document Type: Article

References (52)

1. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM,. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8 (7): 497-511.
2. Arnold RS, Sun CQ, Richards JC, et al. Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment. Prostate 2009; 69 (1): 1-11.
3. Costello LC, Franklin RB,. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: Connecting the dots. Mol Cancer 2006; 5: 17.
4. Nelson PS,. Predicting prostate cancer behavior using transcript profiles. J Urol 2004; 17 (5 Pt 2): S28-S32; discussion S3.
5. Mackler NJ, Pienta KJ,. Drug insight: Use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2005; 2 (2): 92-100; quiz 1 p following 12.
6. Pienta KJ, Smith DC,. Advances in prostate cancer chemotherapy: A new era begins. CA Cancer J Clin 2005; 55 (5): 300-318; quiz 23-25.
7. Stein CA,. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999; 26 (5 Suppl. 17): 3-7.
8. Fojo T, Menefee M,. Mechanisms of multidrug resistance: The potential role of microtubule-stabilizing agents. Ann Oncol 2007; 18 (Suppl. 5): v3-v8.
9. Fulda S, Debatin KM,. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25 (34): 4798-4811.
10. Hernandez-Vargas H, Palacios J, Moreno-Bueno G,. Molecular profiling of docetaxel cytotoxicity in breast cancer cells: Uncoupling of aberrant mitosis and apoptosis. Oncogene 2007; 26 (20): 2902-2913.
11. Wang LG, Liu XM, Kreis W, Budman DR,. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 1999; 44 (5): 355-361.
12. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, Wimalasena J,. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998; 273: 4928-4936.
13. Lindsay J, Esposti MD, Gilmore AP,. Bcl-2 proteins and mitochondria-Specificity in membrane targeting for death. Biochim Biophys Acta 2011; 1813 (4): 532-539.
14. Haldar S, Chintapalli J, Croce CM,. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56 (6): 1253-1255.
15. Tait SW, Green DR,. Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11 (9): 621-632.
16. Pedersen PL,. The cancer cell's "power plants" as promising therapeutic targets: An overview. J Bioenerg Biomembr 2007; 39 (1): 1-12.
17. Green DR, Reed JC,. Mitochondria and apoptosis. Science 1998; 281 (5381): 1309-1312.
18. Ow YP, Green DR, Hao Z, Mak TW,. Cytochrome c: Functions beyond respiration. Nat Rev Mol Cell Biol 2008; 9 (7): 532-542.
19. Beuzeboc P, Ropert S, Goldwasser F, Zerbib M,. Management of metastatic castration-resistant prostate cancer following docetaxel. Bull Cancer 2012; [Epub ahead of print].
20. Seruga B, Ocana A, Tannock IF,. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 1: 12-23.
21. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26 (2): 242-245.
22. Beer TM, El-Geneidi M, Eilers KM,. Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther 2003; 3 (3): 261-268.
23. Mazhar D, Waxman J,. Early chemotherapy in prostate cancer. Nat Clin Pract Urol 2008; 5 (9): 486-493.
24. Gleave M, Kelly WK,. High-risk localized prostate cancer: A case for early chemotherapy. J Clin Oncol 2005; 23 (32): 8186-8191.
25. Oh WK,. High-risk localized prostate cancer: Integrating chemotherapy. Oncologist 2005; 10 (Suppl. 2): 18-22.
26. O'Brien C, True LD, Higano CS, Rademacher BL, Garzotto M, Beer TM,. Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. Am J Clin Pathol 2010; 133 (4): 654-661.
27. Qian DZ, Huang CY, O'Brien CA, Coleman IM, Garzotto M, True LD, Higano CS, Vessella R, Lange PH, Nelson PS, Beer TM,. Prostate cancer-associated gene expression alterations determined from needle biopsies. Clin Cancer Res 2009; 15: 3135-3142.
28. Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Nelson PS,. Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: Identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 2007; 13: 5825-5833.
29. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK,. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 5233-5240.
30. Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ,. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res 2010; 70: 3239-3248.
31. Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM,. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 2010; 70: 433-442.
32. Garzotto M, Higano CS, O'Brien C, Rademacher BL, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM,. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010; 116: 1699-1708.
33. Mhaidat NM, Zhang XD, Jiang CC, Hersey P,. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res 2007; 13 (4): 1308-1314.
34. Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, Ichijo H, Wimalasena J,. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 1999; 274: 8208-8216.
35. Yamamoto K, Ichijo H, Korsmeyer SJ,. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19 (12): 8469-8478.
36. Goward CR, Nicholls DJ,. Malate dehydrogenase: A model for structure, evolution, and catalysis. Protein Sci 1994; 3 (10): 1883-1888.
37. Reisch AS, Elpeleg O,. Biochemical assays for mitochondrial activity: Assays of TCA cycle enzymes and PDHc. Methods Cell Biol 2007; 80: 199-222.
38. Murphy MP,. How mitochondria produce reactive oxygen species. Biochem J 2009; 417 (1): 1-13.
39. Smeitink J, van den Heuvel L, DiMauro S,. The genetics and pathology of oxidative phosphorylation. Nat Rev Genet 2001; 2 (5): 342-352.
40. Higgins LH, Withers HG, Garbens A, Love HD, Magnoni L, Hayward SW, Moyes CD,. Hypoxia and the metabolic phenotype of prostate cancer cells. Biochim Biophys Acta 2009; 1787: 1433-1443.
41. Hsu PP, Sabatini DM,. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134 (5): 703-707.
42. Kirby DM, Thorburn DR, Turnbull DM, Taylor RW,. Biochemical assays of respiratory chain complex activity. Methods Cell Biol 2007; 80: 93-119.
43. Cosulich S, Clarke P,. Apoptosis: Does stress kill ? Curr Biol 1996; 6 (12): 1586-1588.
44. Johnstone RW, Ruefli AA, Lowe SW,. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108 (2): 153-164.
45. Gilbert LA, Hemann MT,. Chemotherapeutic resistance: Surviving stressful situations. Cancer Res 2011; 71 (15): 5062-5066.
46. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL,. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007; 11: 555-569.
47. Haigis KM, Sweet-Cordero A,. New insights into oncogenic stress. Nat Genet 2011; 43 (3): 177-178.
48. Karin M, Gallagher E,. From JNK to pay dirt: Jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 2005; 57 (4-5): 283-295.
49. Yun H, Kim HS, Lee S, Kang I, Kim SS, Choe W, Ha J,. AMP kinase signaling determines whether c-Jun N-terminal kinase promotes survival or apoptosis during glucose deprivation. Carcinogenesis 2009; 30: 529-537.
50. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
51. Schwarzenbach H, Chun FK, Lange I, Carpenter S, Gottberg M, Erbersdobler A, Friedrich MG, Huland H, Pantel K,. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. Int J Cancer 2007; 120: 1465-1471.
52. Weckermann D, Muller P, Wawroschek F, Krawczak G, Riethmuller G, Schlimok G,. Micrometastases of bone marrow in localized prostate cancer: Correlation with established risk factors. J Clin Oncol 1999; 17 (11): 3438-3443.